Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chimeric Human Papillomavirus Type 16 (HPV-16) L1 Particles Presenting the Common Neutralizing Epitope for the L2 Minor Capsid Protein of HPV-6 and HPV-16

12 Jul 2003

Abstract excerpt

Both the Human papillomavirus (HPV) major (L1) and minor (L2) capsid proteins have been well investigated as potential vaccine candidates. The L1 protein first oligomerizes into pentamers, and these capsomers assemble into virus-like particles (VLPs) that are highly immunogenic. Here we examine the potential of using HPV type 16 (HPV-16) L1 subunits to display a well-characterized HPV-16 L2 epitope...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Disease Management and Epidemiology
Share to Herpesvirus Infections and Treatments
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12857908
DOI: 10.1128/jvi.77.15.8386-8393.2003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chimeric Human Papillomavirus Type 16 (HPV-16) L1 Particles Presenting the Common Neutralizing Epitope for the L2 Minor Capsid Protein of HPV-6 and HPV-16PMID 12857908Read ↗

Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus VaccinesSemantic proximity Read ↗

Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?Semantic proximity Read ↗

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated DiseasesSemantic proximity Read ↗

Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like ParticlesSemantic proximity Read ↗

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)Semantic proximity Read ↗

Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.Semantic proximity Read ↗

Substitution of Human Papillomavirus Type 16 L2 Neutralizing Epitopes Into L1 Surface Loops: The Effect on Virus-Like Particle Assembly and ImmunogenicitySemantic proximity Read ↗

Identification of a Human Papillomavirus Type 16-Specific Epitope on the C-Terminal Arm of the Major Capsid Protein L1Semantic proximity Read ↗

L2 epitope presenting virus-like particles as broad- spectrum vaccine candidates targeting genus beta human papillomavirusesSemantic proximity Read ↗

RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine CandidatesSemantic proximity Read ↗

Characterization of a Major Neutralizing Epitope on Human Papillomavirus Type 16 L1Semantic proximity Read ↗

Modification of human papillomavirus‐like particle vaccine by insertion of the cross‐reactive L2‐epitopesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.